Literature DB >> 10421620

Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan.

R F Tyndale1, Y Li, N Y Li, E Messina, S Miksys, E M Sellers.   

Abstract

We investigated the enzymatic function, stability, and regional distribution of rat brain cytochrome P-450 (CYP) 2D1 activity. CYP2D1 is the homolog of human CYP2D6, a genetically variable enzyme that activates or inactivates many clinical drugs acting on the central nervous system (e.g., antidepressants, monoamine oxidase inhibitors, serotonin uptake inhibitors, and neuroleptics), drugs of abuse (e.g., amphetamine and codeine), neurotoxins (e.g., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1,2,3, 4-tetrahydroquinoline), and endogenous neurochemicals (e.g., tryptamine). The CYP2D family has been identified in rodent, canine, and primate brain. Conversion of dextromethorphan to dextrorphan by rat brain membranes was assayed by HPLC and was dependent on NADPH, protein concentration, and incubation time. Significant loss of activity was observed in some homogenizing buffers and after freezing of whole tissues or membrane preparations. Dextromethorphan (0.5-640 microM) metabolism was mediated by high- and low-affinity enzyme systems; K(m1) was 2.7 +/- 2.6 and K(m2) was 757 +/- 156 microM (n = 3 rats, mean +/- S.E.). The enzyme activity was significantly (p <.01) and stereoselectively inhibited by CYP2D1 inhibitors quinine and quinidine (not by CYP2C or CYP3A inhibitors), and by anti-CYP2D6 peptide antiserum (not by anti-CYP2C, -CYP2B, or -CYP3A antibodies). The enzymatic activity demonstrated significant brain regional variation (n = 10 regions, p <.001). These data characterize CYP2D1-mediated dextromethorphan metabolism in rat brain and suggest that localized metabolism of other CYP2D1 substrates (drugs, neurotoxins, and possibly endogenous compounds) within the brain will occur. In humans, CYP2D6 is genetically polymorphic; the variable expression of brain CYP2D6 may result in interindividual differences in central drug and neurotoxin metabolism, possibly contributing to interindividual differences in drug effects and neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421620

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  18 in total

Review 1.  Drug-metabolizing cytochrome P450s in the brain.

Authors:  Sharon L Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

2.  Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.

Authors:  Amandeep Mann; Rachel F Tyndale
Journal:  Eur J Neurosci       Date:  2010-03-22       Impact factor: 3.386

3.  Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metformin.

Authors:  Y H Choi; M G Lee
Journal:  Br J Pharmacol       Date:  2006-08-29       Impact factor: 8.739

4.  Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2008-07-30       Impact factor: 7.853

5.  Cytochrome P450 3A Enzymes Catalyze the O6-Demethylation of Thebaine, a Key Step in Endogenous Mammalian Morphine Biosynthesis.

Authors:  Valerie M Kramlinger; Mónica Alvarado Rojas; Tatsuyuki Kanamori; F Peter Guengerich
Journal:  J Biol Chem       Date:  2015-07-08       Impact factor: 5.157

Review 6.  Cytochrome P450-mediated drug metabolism in the brain.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

7.  First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo.

Authors:  Kaidi Zhou; Jibran Y Khokhar; Bin Zhao; Rachel F Tyndale
Journal:  Biochem Pharmacol       Date:  2013-04-23       Impact factor: 5.858

Review 8.  Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases.

Authors:  Chaitali Ghosh; Vikram Puvenna; Jorge Gonzalez-Martinez; Damir Janigro; Nicola Marchi
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

9.  Lycopene increases metabolic activity of rat liver CYP2B, CYP2D and CYP3A.

Authors:  Kristýna Nosková; Gabriela Dovrtělová; Ondřej Zendulka; Markéta Strakošová; Ondřej Peš; Jan Juřica
Journal:  Pharmacol Rep       Date:  2020-01-13       Impact factor: 3.024

10.  Dextromethorphan differentially affects opioid antinociception in rats.

Authors:  Shiou-Lan Chen; Eagle Yi-Kung Huang; Lok-Hi Chow; Pao-Luh Tao
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.